Related Experiment Video
Updated: May 16, 2025
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
SLAMF7 Restrains Pro-Inflammatory Macrophage Activation to Counteract Doxorubicin-Induced Cardiotoxicity
Ao Liu1, Peiyuan Bai2, Hongmin You3
1Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases and Institutes of Biomedical Sciences, Fudan University, Shanghai, China; State Key Laboratory of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China; NHC Key Laboratory of Ischemic Heart Diseases, Shanghai, China; Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China; Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai Institute of Medical Imaging, Shanghai, China.
Abstract:
Doxorubicin-induced cardiotoxicity (DIC) poses a significant challenge in cancer treatment. This study investigated the role of SLAMF7 in DIC, particularly in macrophage-mediated inflammation. Using SLAMF7 knockout mice, we found that SLAMF7 deficiency exacerbates DIC and amplifies inflammatory responses. Mechanistically, SLAMF7 interacts with TNF receptor-associated factor 6 to attenuate nuclear factor κB signaling, reducing oxidative stress and proinflammatory cytokines. Notably, administering recombinant SLAMF7 protein effectively mitigated DIC. These findings underscore the critical role of SLAMF7 in protecting against DIC, positioning it as a promising therapeutic target.
Insights
SLAMF7 protects against doxorubicin-induced cardiotoxicity (DIC) by reducing inflammation. Restoring SLAMF7 levels effectively mitigated heart damage, highlighting its therapeutic potential in cancer treatment.
Area of Science:
- Cardiology
- Oncology
- Immunology
Background:
- Doxorubicin-induced cardiotoxicity (DIC) is a major limitation in cancer therapy.
- Macrophage-mediated inflammation plays a key role in DIC pathogenesis.
Purpose of the Study:
- To investigate the role of SLAMF7 in doxorubicin-induced cardiotoxicity.
- To elucidate the underlying mechanisms of SLAMF7's protective effects.
Main Methods:
- Utilized SLAMF7 knockout mice to assess cardiotoxicity.
- Examined the interaction between SLAMF7 and TNF receptor-associated factor 6 (TRAF6).
- Measured nuclear factor κB (NF-κB) signaling, oxidative stress, and cytokine levels.
- Administered recombinant SLAMF7 protein to evaluate therapeutic efficacy.
Main Results:
- SLAMF7 deficiency exacerbated DIC and amplified inflammatory responses.
- SLAMF7 interacts with TRAF6 to attenuate NF-κB signaling.
- Reduced oxidative stress and proinflammatory cytokines were observed in the presence of SLAMF7.
- Recombinant SLAMF7 protein administration mitigated DIC.
Conclusions:
- SLAMF7 plays a critical protective role against DIC.
- SLAMF7 acts by modulating macrophage-mediated inflammation via the TRAF6/NF-κB pathway.
- SLAMF7 represents a promising therapeutic target for preventing and treating doxorubicin-induced cardiotoxicity.
